Annette K Larsen

Summary

Country: France

Publications

  1. ncbi Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models
    Amélie Petitprez
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75012, France
    Curr Pharm Des 19:958-64. 2013
  2. ncbi Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
    Annette K Larsen
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Hopital Saint Antoine, Paris 75012, France
    Pharmacol Ther 131:80-90. 2011
  3. ncbi EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
  4. ncbi Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Institut National de la Santé et de la Recherche Médicale U938, Paris, France
    Mol Cancer Ther 10:1481-9. 2011
  5. ncbi The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
  6. ncbi From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
  7. ncbi Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem J 437:63-73. 2011
  8. ncbi Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
  9. ncbi Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
  10. ncbi The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators
    Céline J Rocca
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem Pharmacol 80:335-43. 2010

Collaborators

Detail Information

Publications13

  1. ncbi Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models
    Amélie Petitprez
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75012, France
    Curr Pharm Des 19:958-64. 2013
    ..These results suggest that chemotherapy exposure may lead to creation of novel targets which could be exploited therapeutically...
  2. ncbi Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
    Annette K Larsen
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Hopital Saint Antoine, Paris 75012, France
    Pharmacol Ther 131:80-90. 2011
    ....
  3. ncbi EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
    ..We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling...
  4. ncbi Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Institut National de la Santé et de la Recherche Médicale U938, Paris, France
    Mol Cancer Ther 10:1481-9. 2011
    ..Taken together, our results provide a mechanistic basis to support clinical trials of PM01183 alone or in combination with cisplatin...
  5. ncbi The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
    ..The synthesis of these data allows us to conceive a future development focused on translational research...
  6. ncbi From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  7. ncbi Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem J 437:63-73. 2011
    ..These findings identify ATR as a central co-ordinator of the DNA-damage response to S23906, and provide a mechanistic rationale for combinations of S23906 and similar agents with checkpoint abrogators...
  8. ncbi Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
    ..The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer...
  9. ncbi Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
    ..A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials...
  10. ncbi The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators
    Céline J Rocca
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem Pharmacol 80:335-43. 2010
    ..We further show that NER activity can be up-regulated without changes in ERCC1 expression...
  11. ncbi Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  12. ncbi Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
    Alexandre E Escargueil
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    J Cell Sci 121:1275-83. 2008
    ..Together, our findings provide novel insights into the subsequent fate of the stalled RNA polymerase II and demonstrate the essential role of the recycling process for transcriptional reinitiation and viability of mammalian cells...
  13. ncbi Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy
    Andrzej Skladanowski
    Group of Cancer Biology and Therapeutics, INSERM U673 and Université Pierre et Marie Curie, Hopital Saint Antoine, Paris, France
    Cell Cycle 6:2268-75. 2007
    ....